Enzyme therapy aims to fight wasting in pancreatic cancer patients
NCT ID NCT04098237
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether adding a high-dose pancreatic enzyme replacement (Pancreaze) to standard care can help patients with advanced pancreatic cancer who have weight loss and trouble digesting food. About 36 adults will take the enzymes with meals and snacks for 8 weeks. The goal is to see if patients can stick with the therapy and if it helps stabilize weight, improve nutrition, and quality of life.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Cedars-Sinai Medical Center
Los Angeles, California, 90048, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a pill rouse the immune system against pancreatic cancer?
- A sound wave that could expose hidden pancreatic cancer?
- Can a Two-Target antibody shrink Hard-to-Treat cancers?
- Targeted chemotherapy pump takes fight directly to pancreatic cancer liver tumors
- Light-Activated therapy targets pancreatic tumors during surgery
- Engineered immune cells take aim at Mesothelin-Positive tumors